VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
about
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsNew immunotherapies targeting the PD-1 pathwayCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyPD-1 and its ligands are important immune checkpoints in cancerElevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer CellsImmune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.Immunotherapeutic approaches for hepatocellular carcinomaVascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytesThe Role of Adaptive Immunity in the Efficacy of Targeted Cancer TherapiesA multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid CancerEvaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancerTrial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.PD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapyTGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment.Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib.PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease.Immunotherapy in Sarcoma: Future Horizons.PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.Immunological landscape and immunotherapy of hepatocellular carcinoma.Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.New agents on the horizon in gastric cancer.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Vaccine-based immunotherapeutic approaches to gliomas and beyond.Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy.Reversing T-cell Dysfunction and Exhaustion in Cancer.Chemotherapy for advanced gastric cancer: future perspective in Japan.The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?Endothelial epsins as regulators and potential therapeutic targets of tumor angiogenesis.Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I studyVessel pruning or healing: endothelial metabolism as a novel target?Sunitinib in kidney cancer: 10 years of experience and development.Strategies to overcome therapeutic resistance in renal cell carcinoma.Barriers to Radiation-Induced In Situ Tumor Vaccination.
P2860
Q26996518-8806985A-6EBF-4A35-B988-AF6F75F10B50Q27010018-DEB72E99-2E4E-4D08-A052-D54D5DB69673Q28066199-0DDCC968-7D30-423F-A822-838785491D6CQ28069485-21628E39-5908-497A-AE0B-A05FB224A145Q28553961-8F8789D2-15F9-41AA-8D3C-7E68C7391D65Q30275254-C2304BD8-BC32-478F-958C-D00357D3BD44Q33779723-0FF84A37-F79F-41C4-B99C-696D90677619Q36344920-D2A4DA03-23AB-4963-8D10-D2A644CB8DAEQ36535465-BB77233E-E8D6-49FB-9466-2B4412A93B92Q36777149-57203215-2206-4DDD-AEE5-15E7CE42DCA3Q37057942-14CECC93-E495-4493-8530-0A42AD6F3BD0Q37079133-A607D890-C283-4FC9-BD14-7A26DB3D075DQ37079141-49ADF235-CD1D-4D4A-9D47-F72BBFE7A0FFQ37179971-9B945C05-87CD-44D2-BA37-356746FCF6A6Q37277182-F95B1A17-F10A-4AB0-9571-2F19E588F107Q37516448-E9326C04-A724-4591-AB1F-32F34C9660C9Q37687194-34E0CE19-80E7-4357-BEE6-48F9CEFD7568Q37687323-0AC73610-CAC4-4A94-A964-920AD9688289Q37725613-11C5237E-8D44-4884-8EF5-D35CA2F06AEBQ38413904-12BF8565-24B5-4431-99E7-5F33D195EF6EQ38514440-923AF066-27CD-472B-9A01-D3C1E4DE5F62Q38539063-C8D618A6-1365-485D-A726-B1B170FF814CQ38596093-56109718-7F96-4C5E-B958-1802A1F64ACDQ38607549-6558C458-440A-4159-858C-2D7FD96FF80EQ38611895-FE346035-44EE-4266-9678-6DBA74B24245Q38728953-00B24A1E-0FD3-44B0-9823-0C57C9867E12Q38759129-F1CE1025-3101-4471-88E2-98774651AE38Q38769021-C4B8B8E7-9972-4C15-9366-2DB236439139Q38789860-94228B2D-B5FA-4BAD-872E-A244AB328DFFQ38795278-A809BEA3-A85A-49F9-80EE-4B690EB8A7C2Q38809776-7C493862-AB34-4DCB-A3CD-C766B808B5E6Q38815071-8D2CBCFB-56A5-4562-8DD7-BA55102AB881Q38831655-44D03726-05C0-488E-AA4F-B7A607E5C63CQ38835601-2C6CB551-D8D7-4B41-9549-56EB71BDECD5Q38939975-0CB62192-88C8-4EF1-84E0-EAF9DFFE1A08Q38979882-8C6AE756-F328-431B-B720-FA3B8CC5019AQ39024164-AFB8F334-37EF-4E2A-B6D2-F0D04EB0B345Q39038214-FB7842D4-4337-4442-B388-C8D3EC22F2D1Q39089402-E8454755-B6DB-4BF7-8FD6-E5532692FBB4Q39203685-2ACE4D60-3350-4E5D-8230-806DADF35A4B
P2860
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
@ast
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
@en
type
label
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
@ast
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
@en
prefLabel
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
@ast
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
@en
P2093
P2860
P50
P356
P1476
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
@en
P2093
Anne Berger
Anne-Laure Pointet
Christian Stockmann
Corinne Tanchot
Elie Marcheteau
Franck Zinzindohoue
Hideo Yagita
Mevyn Nizard
Nadine Benhamouda
Orianne Colussi
P2860
P304
P356
10.1084/JEM.20140559
P407
P577
2015-01-19T00:00:00Z